Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Axsome Therapeutics (AXSM) reported a Q3 loss of $1.34 per share, which was better than the Zacks Consensus Estimate of a $1.38 loss. This is a slight increase from the $1.32 loss per share a year ago.
November 12, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics reported a Q3 loss of $1.34 per share, better than the expected $1.38 loss, and topped revenue estimates.
The better-than-expected earnings per share loss and revenue exceeding expectations are positive indicators for Axsome Therapeutics. This could lead to a short-term increase in stock price as investors react to the earnings beat.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100